Product
Hyaluronidase-Fihj
1 clinical trial
2 indications
Indication
Hematologic MalignancyIndication
Refractory Hematologic MalignancyClinical trial
ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic MalignanciesStatus: Withdrawn, Estimated PCD: 2023-07-05